Brief: Curevac And MD Anderson To Cooperate On Developing Novel Cancer Vaccines

CureVac NV

16/04/2024 12:02

April 16 (Reuters) - CureVac NV  5CV.DE :
    * CUREVAC AND MD ANDERSON ENTER STRATEGIC COLLABORATION TO 
DEVELOP NOVEL CANCER VACCINES
    * COLLABORATION AIMS TO DEVELOP NOVEL, OFF--SHELF,
MRNA-BASED
CANCER VACCINES IN SELECTED HEMATOLOGICAL AND SOLID CANCERS WITH
HIGH UNMET MEDICAL NEED
    * CUREVAC HAS WORLDWIDE EXCLUSIVE RIGHTS TO LATE-STAGE
DEVELOPMENT, COMMERCIALIZATION, OR PARTNERING OF CANCER VACCINE
CANDIDATES
    * MD ANDERSON IS ELIGIBLE FOR CERTAIN DOWNSTREAM PAYMENTS
BASED ON
POTENTIAL FUTURE COMMERCIALIZATION

Source text for Eikon:  ID:nEQ7hjvCMa 
Further company coverage:  5CV.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))